News & Updates

Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD

11 Aug 2022

In patients with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD), treatment with canagliflozin safely decreases the risk of developing end-stage renal disease, reports a new Japan study.

Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD

11 Aug 2022

TNF-α antagonists superior to vedolizumab, ustekinumab for endoscopic healing in CD

10 Aug 2022 by

The tumour necrosis factor-alpha (TNF-α) antagonist therapies adalimumab and infliximab are more effective than vedolizumab and ustekinumab in achieving endoscopic healing (EH) at 1 year among patients with moderate-to-severe Crohn’s disease (CD), a recent study has shown.

TNF-α antagonists superior to vedolizumab, ustekinumab for endoscopic healing in CD

10 Aug 2022

Tools to predict adverse drug reactions in older adults lacking

10 Aug 2022

There is currently no standard and well-validated tool to predict adverse drug reactions (ADRs) in older adults, reports a recent meta-analysis.

Tools to predict adverse drug reactions in older adults lacking

10 Aug 2022

Ketamine holds up against fentanyl for procedural sedation in outpatient surgical abortion

10 Aug 2022

Intravenous treatment with ketamine is as good as that with fentanyl for procedural sedation in patients undergoing first-trimester outpatient surgical abortion, as reflected in patients’ satisfaction with their anaesthesia, according to a study.

Ketamine holds up against fentanyl for procedural sedation in outpatient surgical abortion

10 Aug 2022

Methenamine hippurate as good as antibiotic prophylaxis for recurrent UTI

10 Aug 2022 by

Daily antibiotics are the current guideline-recommended standard for urinary tract infection (UTI). Interestingly, in the randomized, open-label ALTAR trial presented at EAU 2022, the urinary antiseptic methenamine hippurate was noninferior to antibiotic prophylaxis in women with recurrent UTI.

Methenamine hippurate as good as antibiotic prophylaxis for recurrent UTI

10 Aug 2022

Dronedarone matches up to Asians with AF, atrial flutter

09 Aug 2022 by

Asians with atrial fibrillation (AF) or atrial flutter (AFL) do well with dronedarone, which lowers the risk of hospitalization for cardiovascular (CV) events or death from any cause to a similar extent as in non-Asian patients from the ATHENA trial, according to the results of a post hoc analysis.

Dronedarone matches up to Asians with AF, atrial flutter

09 Aug 2022

Men with PsA derive more benefit from MTX+ETN therapy than women

09 Aug 2022 by

Combination therapy with methotrexate (MTX) plus etanercept (ETN) results in more improved outcomes in men than in women with psoriatic arthritis (PsA) for minimal disease activity (MDA) and Psoriatic Arthritis Disease Activity Score (PASDAS), a study has shown.

Men with PsA derive more benefit from MTX+ETN therapy than women

09 Aug 2022

Add-on DPP4i, GLP1Ra as good as insulin for in-hospital diabetes management

08 Aug 2022

The use of dipeptidyl peptidase 4 inhibitors (DPP4i) and sodium glucose co-transporter 2 inhibitors (SGLT2i) for diabetic patients admitted to hospitals yields the same efficacy and safety outcomes as insulin, according to the results of a systematic review and meta-analysis.